Showing results (661-670 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guérin nucleic acid fractionE Kuramoto, O Yano, S ShimadaCancer Immunology, Immunotherapy : CII|January 1, 1992
Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984A H Schrijvers, M Gerretsen, M van Walsum, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1992
Lymphokine production by human melanoma tumor-infiltrating lymphocytesM A Salmeron, T Morita, H Seki, et al.Cancer Immunology, Immunotherapy : CII|February 28, 2001
Tumour-induced suppression of immune response and its correctionG A Banat, O Christ, B Cochlovius, et al.Cancer Immunology, Immunotherapy : CII|February 28, 2001
The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse modelD A Arenberg, A Zlotnick, S R Strom, et al.Cancer Immunology, Immunotherapy : CII|February 28, 2001
Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genesA Van Pel, E De Plaen, M T Duffour, et al.Cancer Immunology, Immunotherapy : CII|February 28, 2001
Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patientL M Real, P Jimenez, A Kirkin, et al.Cancer Immunology, Immunotherapy : CII|March 22, 2001
CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cellsR D Lopez, E K Waller, P H Lu, et al.Cancer Immunology, Immunotherapy : CII|March 22, 2001
The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cellsS Heinzel, D Rea, R Offringa, et al.Cancer Immunology, Immunotherapy : CII|March 22, 2001
Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2F Turatti, D Mezzanzanica, E Nardini, et al.Pageof 650